Custom Search

Ziprasidone News

Geodon Effective In Treating Schizophrenia Symptoms With A Postive Effect On Patients' Weight, Cholesterol And Triglycerides, Study Shows

Pfizer today issued the following statement upon publication of results from the second phase of the National Institute of Mental Health (NIMH) study, Antipsychotic Trials of Intervention Effectiveness (CATIE), in patients with...

One Third Of Patients Who Stop Treatment For Schizophrenia Early Do So Due To Poor Response

A third of patients treated for schizophrenia who stop taking their medication early do so because they do not feel any significant improvement or because their symptoms are worsening.

Old and New Schizophrenia Drugs: Study Shows Patient Satisfaction Is About the Same

Patients are about as happy with new schizophrenia drugs, some of which are a decade old, as they are with a drug from a half century ago, the initial results of a new study show.

Yale Study Reconciles Two Models Of Schizophrenia

Yale School of Medicine researchers published areport this month in the Archives of General Psychiatry that highlightsthe interplay of two brain signaling systems, glutamate and dopamine,in psychosis and cognitive function.

Long-Term Study Shows Pfizer's Geodon Has Comparable Efficacy With Fewer Adverse Metabolic Effects Than Zyprexa

The antipsychotic Geodon® (ziprasidone HCl) is as effective as Zyprexa (olanzapine) in maintenance treatment of patients with schizophrenia, but has significantly less adverse effect on body weight, cholesterol, and insulin,...

Displaying results 6 to 10 out of 11

< Previous




Next >

Use of this site is subject to the following terms of use